- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01615705
Biomarker Sub Study of the Compression Stockings to Prevent the Post-Thrombotic Syndrome (SOX) Trial (Bio-SOX)
June 6, 2012 updated by: Dr. Susan Kahn, Sir Mortimer B. Davis - Jewish General Hospital
The Etiologic Role of Inflammation, Thrombophilia and Fibrinolysis in the Post-thrombotic Syndrome: The Bio-SOX Sub Study
The purpose of this study is to evaluate whether biomarkers of inflammation, genetic thrombophilia and coagulation activation influence Post-Thrombotic Syndrome development in patients with symptomatic proximal deep venous thrombosis.
Study Overview
Status
Completed
Conditions
Detailed Description
The post-thrombotic syndrome (PTS) is a frequent, burdensome and costly condition that occurs in about one third of patients after an episode of deep vein thrombosis (DVT).
Affected patients have chronic leg pain and swelling, and sometimes develop skin ulcers.
Poor understanding of the pathophysiology and predictors of PTS has hampered progress in its prevention and treatment.
Biomarkers reflective of inflammation, genetic thrombophilia and coagulation activation may be of value in predicting PTS development in patients with DVT; they may also provide insight into understanding the underlying mechanisms of PTS, which could result in the development and testing of novel therapies to prevent and treat PTS.
Study Type
Observational
Enrollment (Actual)
803
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
British Columbia
-
Victoria, British Columbia, Canada, V8R 4R2
- Victoria Heart Institute Foundation
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R2H 2A6
- St. Boniface General Hospital
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3H 1V7
- QE II Health Sciences Centre
-
-
Ontario
-
Hamilton, Ontario, Canada, L8L 2X2
- Hamilton Health Sciences - General Hospital
-
Hamilton, Ontario, Canada, L8N 3Z5
- Hamilton Health Sciences - Chedoke Division
-
Hamilton, Ontario, Canada, L8N 3Z5
- Hamilton Health Sciences - McMaster University Medical Centre
-
Hamilton, Ontario, Canada, L8N 3Z5
- St. Joseph's Healthcare Hamilton
-
Hamilton, Ontario, Canada, L8V 1C3
- Hamilton Health Sciences - Henderson General Hospital
-
London, Ontario, Canada, N6A 4G5
- London Health Sciences Centre
-
Ottawa, Ontario, Canada, K1Y 4E9
- The Ottawa Hospital, Civic Campus
-
Toronto, Ontario, Canada, M4N 3M5
- Sunnybrook & Women's College Health Sciences Centre
-
Toronto, Ontario, Canada, M5G 2C4
- University Health Network - Toronto General Hospital
-
-
Quebec
-
Longueuil, Quebec, Canada, J4M 2A5
- Centre Hospitalier Pierre-Boucher
-
Montreal, Quebec, Canada, H4J 1C5
- Hôpital du Sacré-Coeur de Montreal
-
Montreal, Quebec, Canada, H3T 1M5
- St. Mary's Hospital Center
-
Montreal, Quebec, Canada, H3G 1A4
- Montreal General Hospital - McGill University Health Centre
-
Montreal, Quebec, Canada, H1T 4M1
- Hôpital Maisonneuve-Rosemont
-
Montreal, Quebec, Canada, H2L 4M1
- Centre Hospitalier de l'Université de Montréal - Hôpital Notre Dame
-
Montreal, Quebec, Canada, H3T 1E2
- Sir Mortimer B. Davis -Jewish General Hospital
-
Montreal, Quebec, Canada
- Centre Hospitalier de l'Université de Montréal - Hôpital Hôtel-Dieu
-
Montreal, Quebec, Canada
- Royal Victoria Hospital - McGill University Health Centre
-
Quebec City, Quebec, Canada, G1J 1Z4
- Centre hospitalier affilié universitaire de Québec, Hôpital de l'Enfant-Jésus
-
-
-
-
Michigan
-
Detroit, Michigan, United States, 48202
- Henry Ford Health System
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke University Medical Center
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73104
- Oklahoma University Health Sciences Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Subjects previously enrolled in the SOX Trial (ClinicalTrials.gov
Identifier NCT00143598)
Description
Inclusion Criteria:
- Consecutive patients with a first, symptomatic, objectively confirmed proximal DVT diagnosed within the last 14 days (with or without concurrent distal DVT or pulmonary embolism)
- Who have no contraindications to standard treatment with heparin and/or warfarin, and
- Who provide informed consent to participate
Exclusion Criteria:
- Contraindication to compression stockings Limited lifespan (estimated < 6 months)
- Geographic inaccessibility preventing return for follow-up visits
- Inability to apply stockings daily and unavailability of a caregiver to apply stockings daily
- Treatment of acute DVT with thrombolytic agents
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
---|
Blood Draw
SOX Subjects: The cohort consists of original subjects from the SOX Trial who consented to participate in the sub study. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Markers of Inflammation
Time Frame: Baseline
|
Blood samples drawn at baseline, 1 and 6-mths to evaluate the relationship between CRP, ICAM, IL-6, IL-10 with the subsequent development of PTS.
|
Baseline
|
Markers of Inflammation
Time Frame: 1-mth follow up
|
Blood samples drawn at baseline, 1 and 6-mths to evaluate the relationship between CRP, ICAM, IL-6, IL-10 with the subsequent development of PTS.
|
1-mth follow up
|
Markers of Other Thrombophilia
Time Frame: 6-mth follow up
|
Blood samples drawn at 6-mths to evaluate the relationship between D-Dimer, VIII, Lupus anticoagulant, IgG, IgM with the subsequent development of PTS.
|
6-mth follow up
|
Markers of Inflammation
Time Frame: 6-month follow up
|
Blood samples drawn at baseline, 1 and 6-mths to evaluate the relationship between CRP, ICAM, IL-6, IL-10 with the subsequent development of PTS.
|
6-month follow up
|
Markers of Other Thrombophilia
Time Frame: 6-month follow up
|
Blood samples drawn at 6-mths to evaluate the relationship between D-Dimer, VIII, Lupus anticoagulant, IgG, IgM with the subsequent development of PTS.
|
6-month follow up
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Susan R Kahn, M.D., M.Sc., Sir Mortimer B. Davis - Jewish General Hospital
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Kahn SR, Shbaklo H, Shapiro S, Wells PS, Kovacs MJ, Rodger MA, Anderson DR, Ginsberg JS, Johri M, Tagalakis V; SOX Trial Investigators. Effectiveness of compression stockings to prevent the post-thrombotic syndrome (the SOX Trial and Bio-SOX biomarker substudy): a randomized controlled trial. BMC Cardiovasc Disord. 2007 Jul 24;7:21. doi: 10.1186/1471-2261-7-21.
- Rabinovich A, Cohen JM, Cushman M, Kahn SR; BioSOX Investigators. Association between inflammation biomarkers, anatomic extent of deep venous thrombosis, and venous symptoms after deep venous thrombosis. J Vasc Surg Venous Lymphat Disord. 2015 Oct;3(4):347-353.e1. doi: 10.1016/j.jvsv.2015.04.005. Epub 2015 Aug 1.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2004
Primary Completion (Actual)
September 1, 2010
Study Completion (Actual)
February 1, 2012
Study Registration Dates
First Submitted
June 1, 2012
First Submitted That Met QC Criteria
June 6, 2012
First Posted (Estimate)
June 11, 2012
Study Record Updates
Last Update Posted (Estimate)
June 11, 2012
Last Update Submitted That Met QC Criteria
June 6, 2012
Last Verified
June 1, 2012
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- MOP-89349/NA-5629
- ISRCTN71334751 (REGISTRY: ISRCTN)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Deep Venous Thrombosis
-
Hospital de Clinicas de Porto AlegreCompletedDeep Venous Thromboses | Deep Venous Thrombosis of Left Leg | Deep Venous Thrombosis of Right Leg | Deep Venous Thrombosis Proximal
-
Intermountain Health Care, Inc.TerminatedDeep Vein Thrombosis | Venous Thromboembolism | Deep Venous Thrombosis | Thrombus | Upper Extremity Deep Venous ThrombosisUnited States
-
Tong ZhuNot yet recruitingDeep Vein Thrombosis | Deep Venous Insufficiency
-
Maastricht University Medical CenterTerminatedRandomized Clinical Trial | Deep-Venous Thrombosis | Deep Venous StentingNetherlands
-
Imperial College LondonWithdrawnDeep Vein Thrombosis | Deep Venous Thrombosis of LegUnited Kingdom
-
University of Massachusetts, AmherstCompletedDeep Venous Thrombosis of Deep Femoral VeinUnited States
-
Ottawa Hospital Research InstituteUniversity of Alberta; Hamilton Health Sciences Corporation; Queen Elizabeth...CompletedThromboprophylaxis With Rivaroxaban In Patients With Malignancy and Central Venous Lines (TRIM-Line)Cancer | Central Venous Catheter Thrombosis | Upper Extremity Deep Vein ThrombosisCanada
-
University Hospital, BrestCompletedRecurrent Venous Thromboembolism | Idiopathic Deep Vein ThrombosisFrance
-
University of OklahomaPfizerCompleted
-
University of PadovaCompleted